SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company,
is set to present at two healthcare equity conferences in early
September.
Chief Executive Officer Saundra
Pelletier will present at the 2019 Wells Fargo Securities
Healthcare Conference on Wednesday,
September 4, 2019 at 3:00 PM
EDT. The conference will be held at the Weston Copley
Place Hotel in Boston,
MA.
On Tuesday, September 10, 2019 at
4:40 PM EDT, Chief Commercial Officer
Russ Barrans will present at the
21st Annual Rodman & Renshaw Healthcare Conference, sponsored
by H.C. Wainwright, LLC. The conference will be held at the
Lotte New York Palace in New York,
NY.
To access the live and archived webcasts of either presentation,
visit the Investors section of the Evofem Biosciences website at
www.evofem.com. Both webcasts will be archived on the Evofem
website for 90 days following the respective events.
About Evofem Biosciences
Evofem Biosciences, Inc., is a clinical-stage biopharmaceutical
company committed to developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health. The Company is leveraging its proprietary Multipurpose
Vaginal pH Regulator (MVP-R™) platform to develop its first product
candidate, Amphora® (L-lactic acid, citric acid and
potassium bitartrate). Amphora is an investigational MVP-R designed
to regulate vaginal pH within the normal range of 3.5 to 4.5. This
maintains an acidic environment which is inhospitable to sperm as
well as certain viral and bacterial pathogens associated with
sexually transmitted infections but is integral to the survival of
healthy bacteria in the vagina.
Evofem plans to resubmit the Amphora New Drug Application (NDA)
for prevention of pregnancy and vaginal lubrication in the fourth
quarter of 2019. If approved, the Company plans to launch Amphora
in 2020 as the first-in-class MVP-R for hormone-free,
woman-controlled birth control.
This investigational MVP-R is also in development for prevention
of certain sexually transmitted infections. Evofem expects to
report top-line data from AMPREVENCE, the ongoing Phase
2b trial of Amphora to prevent
urogenital acquisition of Chlamydia trachomatis (primary
endpoint) and Neisseria gonorrhea (secondary endpoint) in
women, in the fourth quarter of 2019.
For more information, please visit www.evofem.com.
Amphora® is a registered trademark and MVP-R™ is
a trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements related to the timing of the planned NDA
Amphora re-submission for prevention of pregnancy, potential FDA
approval of Amphora, and the potential commercial launch of
Amphora, the anticipated results of the Phase 2b clinical
trial of Amphora to prevent urogenital acquisition
of Chlamydia trachomatis and Neisseria
gonorrhea in women, and any expected completion date or
general timing for this clinical trial. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from those, express or implied, in
these forward-looking statements. Important factors that could
impair the value of Evofem Biosciences' assets and business are
disclosed in the risk factors contained in its Annual Report on
Form 10-K filed with the Securities and Exchange
Commission and subsequent filings. All forward-looking
statements are expressly qualified in their entirety by such
factors. Evofem Biosciences does not undertake any duty to update
any forward-looking statement except as required by law.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
M: (917) 673-5775
Media Contact
Greg
Jawski
Porter Novelli
Greg.jawski@porternovelli.com
M: (917) 749-4964
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-upcoming-healthcare-conferences-300904789.html
SOURCE Evofem Biosciences, Inc.